Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
He was responsible for launching the company’s last major drug to treat schizophrenia, the antipsychotic Abilify, in 2002. Cobenfy, set to launch in October, will have a list price that would ...
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
BMS said Cobenfy will be available in October at a list price of $1,850 per month ... the price is in line with other ...
More common side effects in people taking Caplyta for schizophrenia include: Mild side effects can occur with Caplyta use. This list doesn’t include all possible mild side effects of the drug.
Historically, powerful people rarely invest in new medications for marginalized populations like those with schizophrenia. When it happens, it feels like the system is finally listening to us ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...